Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency
Source abstract
Abstract
Abstract The transfection potency of lipid nanoparticle (LNP) mRNA systems is critically dependent on the ionizable cationic lipid component. LNP mRNA systems composed of optimized ionizable lipids often display distinctive mRNA‐rich “bleb” structures. Here, it is shown that such structures can also be induced for LNPs containing nominally less active ionizable lipids by formulating them in the presence of high concentrations of pH 4 buffers such as sodium citrate, leading to improved transfection potencies both in vitro and in vivo. Induction of bleb structure and improved potency is dependent on the type of pH 4 buffer employed, with LNP mRNA systems prepared using 300 mm sodium citrate buffer displaying maximum transfection. The improved transfection potencies of LNP mRNA systems displaying bleb structure can be attributed, at least in part, to enhanced integrity of the encapsulated mRNA. It is concluded that enhanced transfection can be achieved by optimizing formulation parameters to improve mRNA stability and that optimization of ionizable lipids to achieve enhanced potency may well lead to improvements in mRNA integrity through formation of the bleb structure rather than enhanced intracellular delivery.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · RNA Research and Splicing
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biochemistry and Molecular Biology University of British Columbia Vancouver British Columbia V6T 1Z4 Canada
Michael Smith Laboratories University of British Columbia Vancouver British Columbia V6T 1Z4 Canada
School of Biomedical Engineering University of British Columbia Vancouver British Columbia V6T 1Z4 Canada
NanoVation Therapeutics Inc. 2405 Wesbrook Mall Vancouver British Columbia V6T 1Z3 Canada
Funding
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
References (30)
Show source-provided references
1. 10.1021/acs.molpharmaceut.2c0036510.1021/acs.molpharmaceut.2c00365 ↗
2. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
3. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
4. 10.1038/s41587-022-01491-z10.1038/s41587-022-01491-z ↗
5. 10.1038/s41586-021-03534-y10.1038/s41586-021-03534-y ↗
6. 10.1186/s12943-021-01348-010.1186/s12943-021-01348-0 ↗
7. 10.1126/science.abm059410.1126/science.abm0594 ↗
8. 10.1038/s41565-021-00898-010.1038/s41565-021-00898-0 ↗
9. 10.1038/nbt.160210.1038/nbt.1602 ↗
10. 10.1016/S0005-2736(00)00343-610.1016/S0005-2736(00)00343-6 ↗
11. 10.1038/nature0468810.1038/nature04688 ↗
12. 10.1002/anie.20120326310.1002/anie.201203263 ↗
13. 10.3390/pharmaceutics1402039810.3390/pharmaceutics14020398 ↗
14. b)Xinyao Du S. M. Ansell US20160376224A1 2016;
15. c)K. E.Benenato US20170210697A1 2017.
16. 10.1007/s11095-004-1873-z10.1007/s11095-004-1873-z ↗
17. 10.1016/S0006-3495(01)76202-910.1016/S0006-3495(01)76202-9 ↗
18. 10.1038/mtna.2012.2810.1038/mtna.2012.28 ↗
19. 10.1021/acsnano.8b0151610.1021/acsnano.8b01516 ↗
20. 10.1038/mtna.2012.2810.1038/mtna.2012.28 ↗
21. 10.1039/C9NR02004G10.1039/C9NR02004G ↗
22. 10.1016/j.bpj.2021.03.01210.1016/j.bpj.2021.03.012 ↗
23. 10.1038/283743a010.1038/283743a0 ↗
24. 10.1021/bi952000v10.1021/bi952000v ↗
25. 10.1021/la960318y10.1021/la960318y ↗
26. 10.1038/s41467-021-26926-010.1038/s41467-021-26926-0 ↗
27. 10.1074/jbc.REV119.00651310.1074/jbc.REV119.006513 ↗
28. 10.1002/anie.20140084710.1002/anie.201400847 ↗
29. 10.1126/science.124188810.1126/science.1241888 ↗
30. 10.1016/0304-4157(79)90012-110.1016/0304-4157(79)90012-1 ↗